Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for apolipoprotein A-II amyloidosis.
5 publications have been identified in PubMed for apolipoprotein A-II amyloidosis. Research spans Basic Science / Preclinical (60%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Codo GR (2026). [PMID: 42043863](https://pubmed.ncbi.nlm.nih.gov/42043863/). *Amyloid*. [Basic Science / Preclinical]
Andreotti G (2025). [PMID: 40945578](https://pubmed.ncbi.nlm.nih.gov/40945578/). *J Mol Biol*. [Basic Science / Preclinical]
Nasr SH (2025). [PMID: 39547356](https://pubmed.ncbi.nlm.nih.gov/39547356/). *Am J Kidney Dis*. [Case Report / Case Series]
Igarashi Y (2025). [PMID: 41083029](https://pubmed.ncbi.nlm.nih.gov/41083029/). *Exp Gerontol*. [Basic Science / Preclinical]
Lin L (2025). [PMID: 40685142](https://pubmed.ncbi.nlm.nih.gov/40685142/). *Nephrology (Carlton)*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 3:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about apolipoprotein A-II amyloidosis
AI-curated news mentioning apolipoprotein A-II amyloidosis
Updated Aug 31, 2026
A rare case study highlights the relationship between hypertriglyceridemia, chronic kidney disease, and proteinuria in a patient with apolipoprotein C-II amyloidosis. This research contributes to the understanding of the disease's impact on kidney function.
A recent study highlights the dual pathology of fibrillary glomerulonephritis and apolipoprotein A-IV amyloidosis, diagnosed using mass spectrometry and DNAJB9 immunohistochemistry. This research contributes to the understanding of these rare diseases and their diagnostic challenges.